ASCRS 2023: Analysis in two subgroups of routine cataract surgery

Video

Edward Hu, MD, PhD, discussed his paper on the single surgeon retrospective comparative analysis of 517 eyes of two subgroups of routine cataract surgery at the 2023 ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Edward Hu, MD, PhD:

Hello, I'm Dr. Edward Hu, cataract specialist with the Wolfe Eye Clinic in Iowa, and I wanted to share with you some results of a paper I presented at the 2023 ASCRS meeting in San Diego. I presented a paper regarding a single surgeon retrospective comparative analysis of 517 eyes in which they were broken down into two subgroups of routine cataract surgery. One group had had prior refractive surgery, either LASIK or PRK versus the second subgroup which had not had prior refractive surgery.

We analyze the outcomes in terms of vision. and understandably, preoperatively, the refractive group had slightly better visual acuities because they had undergone refractive surgery. Postoperatively, interestingly, the refractive group had slightly better visual outcomes than the patients that had not undergone refractive surgery. Our conclusion is that the monofocal IOL, with the aberration-free design of the Bausch + Lomb enVista likely had contributed to these great outcomes in both subgroups.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
© 2025 MJH Life Sciences

All rights reserved.